Calliditas Change To Netincome from 2010 to 2024
| CALT Stock | USD 39.99 1.52 3.95% |
Change To Netincome | First Reported 2010-12-31 | Previous Quarter 14.4 M | Current Value 19.6 M | Quarterly Volatility 18.9 M |
Check Calliditas Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Calliditas main balance sheet or income statement drivers, such as Interest Income of 30.5 M, Depreciation And Amortization of 17.4 M or Interest Expense of 76.9 M, as well as many exotic indicators such as Price To Sales Ratio of 10.95, Dividend Yield of 0.0 or PTB Ratio of 43.63. Calliditas financial statements analysis is a perfect complement when working with Calliditas Therapeutics Valuation or Volatility modules.
Calliditas | Change To Netincome |
Latest Calliditas Therapeutics' Change To Netincome Growth Pattern
Below is the plot of the Change To Netincome of Calliditas Therapeutics over the last few years. It is Calliditas Therapeutics' Change To Netincome historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Calliditas Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Change To Netincome | 10 Years Trend |
|
Change To Netincome |
| Timeline |
Calliditas Change To Netincome Regression Statistics
| Arithmetic Mean | 10,977,608 | |
| Coefficient Of Variation | 172.52 | |
| Mean Deviation | 12,671,744 | |
| Median | 996,000 | |
| Standard Deviation | 18,938,627 | |
| Sample Variance | 358.7T | |
| Range | 70.7M | |
| R-Value | 0.52 | |
| Mean Square Error | 283.2T | |
| R-Squared | 0.27 | |
| Significance | 0.05 | |
| Slope | 2,187,395 | |
| Total Sum of Squares | 5021.4T |
Calliditas Change To Netincome History
About Calliditas Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Calliditas Therapeutics income statement, its balance sheet, and the statement of cash flows. Calliditas Therapeutics investors use historical funamental indicators, such as Calliditas Therapeutics's Change To Netincome, to determine how well the company is positioned to perform in the future. Although Calliditas Therapeutics investors may use each financial statement separately, they are all related. The changes in Calliditas Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Calliditas Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Calliditas Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Calliditas Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Change To Netincome | 14.4 M | 19.6 M |
Pair Trading with Calliditas Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calliditas Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calliditas Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Calliditas Stock
| 0.42 | DMTK | DermTech | PairCorr |
The ability to find closely correlated positions to Calliditas Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calliditas Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calliditas Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calliditas Therapeutics to buy it.
The correlation of Calliditas Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calliditas Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calliditas Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calliditas Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Calliditas Therapeutics Correlation against competitors. For more information on how to buy Calliditas Stock please use our How to Invest in Calliditas Therapeutics guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Calliditas Stock analysis
When running Calliditas Therapeutics' price analysis, check to measure Calliditas Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Calliditas Therapeutics is operating at the current time. Most of Calliditas Therapeutics' value examination focuses on studying past and present price action to predict the probability of Calliditas Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Calliditas Therapeutics' price. Additionally, you may evaluate how the addition of Calliditas Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |
Is Calliditas Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Calliditas Therapeutics. If investors know Calliditas will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Calliditas Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 44.972 | Quarterly Revenue Growth 0.052 | Return On Assets (0.13) | Return On Equity (0.85) |
The market value of Calliditas Therapeutics is measured differently than its book value, which is the value of Calliditas that is recorded on the company's balance sheet. Investors also form their own opinion of Calliditas Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Calliditas Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Calliditas Therapeutics' market value can be influenced by many factors that don't directly affect Calliditas Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Calliditas Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calliditas Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calliditas Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.